Update οおみくろんn the diagnosis and management of systemic lupus erythematosus

A Fanouriakis, N Tziolos, G Bertsias… - Annals of the rheumatic …, 2021 - ard.bmj.com
Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …

Novel paradigms in systemic lupus erythematosus

T Dörner, R Furie - The Lancet, 2019 - thelancet.com
The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

A Fanouriakis, M Kostopoulou, J Andersen… - Annals of the …, 2024 - ard.bmj.com
Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

A Fanouriakis, M Kostopoulou, A Alunno… - Annals of the …, 2019 - ard.bmj.com
Our objective was to update the EULAR recommendations for the management of systemic
lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …

Antiphospholipid syndrome

K Schreiber, S Sciascia, PG De Groot… - Nature reviews Disease …, 2018 - nature.com
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature

C Chatre, F Roubille, H Vernhet, C Jorgensen, YM Pers - Drug safety, 2018 - Springer
Introduction Chloroquine and hydroxychloroquine are widely used in the long-term
treatment of connective tissue disease and usually considered safe. However, chloroquine …

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2 …

RF van Vollenhoven, BH Hahn, GC Tsokos… - The Lancet, 2018 - thelancet.com
Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's …

Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs

G Ruiz-Irastorza, G Bertsias - Rheumatology, 2020 - academic.oup.com
Besides treating acute flares, the management of SLE should aim at preventing organ
damage accrual and drug-associated harms, improving health-related quality of life and …

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

C Gordon, MB Amissah-Arthur, M Gayed… - …, 2018 - academic.oup.com
Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4,
Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …

Physical activity and autoimmune diseases: Get moving and manage the disease

K Sharif, A Watad, NL Bragazzi, M Lichtbroun… - Autoimmunity …, 2018 - Elsevier
Physical activity, by definition, is any skeletal muscle body movement that results in energy
expenditure. In the last few decades, a plethora of scientific evidences have accumulated …